Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To provide an intravenous ribavirin therapeutic option for patients with a probable or
suspected case of viral hemorrhagic fever, specifically Crimean-Congo hemorrhagic fever or
Lassa fever.
Phase:
N/A
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command